JACKSON, Mich., Jan. 16, 2025 /PRNewswire/ -- CMS Energy announced today it will provide 2024 year-end results along with a business and financial outlook at 9:30 a.m. EST on Thursday, February 6, 2025.A webcast of the presentation will be available on CMS Energy's website, cmsenergy.com. An audio replay will be available approximately three hours after the webcast and will be archived for 30 days on CMS Energy's website in the "Investor Relations" section.CMS Energy (NYSE: CMS) is a Michigan-based energy c ...

CMS Energy Corporation (CMS) is making strategic investments to enhance its operations. CMS is also benefiting from delivering high-quality services to its consumers. The company is expanding its renewable power portfolio while eliminating coal-generating units.However, this Zacks Rank #3 (Hold) company is exposed to unfavorable costs associated with the shutdown of solid waste disposal facilities for coal ash.Factors Acting in Favor of CMS CMS Energy is investing heavily in infrastructure renovations and r ...

Medicare and Medicaid Coverage for Zepbound - Medicare Part D plans can now cover Eli Lilly's Zepbound for obstructive sleep apnea (OSA), expanding access to the drug which was previously not covered for weight loss [1][2] - Medicare Part D coverage for obesity drugs like Zepbound requires FDA approval for an additional medically accepted purpose, and prior authorization may be used to ensure proper usage [3] - State Medicaid programs must cover Zepbound if prescribed for OSA and Eli Lilly has signed the Medicaid drug rebate agreement, but coverage is not required if prescribed for weight loss [7][8] FDA Approval and Market Impact - Zepbound was approved by the FDA on Dec 20 for obesity and moderate-to-severe OSA, making it the first drug treatment for an estimated 20 million people with these conditions [4] - Demand for Zepbound has soared over the past year despite its $1,000 price tag before insurance [1] Comparative Coverage and Industry Trends - Medicare Part D plans also cover Novo Nordisk's Wegovy for its approved use of lowering cardiovascular risks, while diabetes counterparts Ozempic and Mounjaro are covered by Medicare and most insurance plans [5] - Both Eli Lilly and Novo Nordisk are studying their weight loss drugs for additional conditions like fatty liver disease, chronic kidney disease, and sleep apnea, which would require late-stage trial results and FDA approval for coverage [6] Policy and Cost Implications - The Biden administration proposed a rule in November to allow Medicare and Medicaid coverage for weight loss drugs, potentially giving millions access to weekly injectables but costing taxpayers up to $35 billion over the next decade [9]

CMS Energy Corporation (CMS) recently revealed that its primary subsidiary, Consumer Energy, has introduced a plan to upgrade its natural gas system, which provides gas to more than 1.8 million homes and businesses in Michigan.Details of CMS’ PlanPer the plan, the company will replace up to 10,000 old gas lines and add valves that can be operated remotely to handle emergencies faster. These improvements will make the system safer, more reliable and better for the environment while keeping it affordable for ...

At Energy Profits in Dividends, we seek to generate a 7%+ income yield by investing in a portfolio of energy stocks while minimizing our risk of principal loss. By subscribing, you will get access to our best ideas earlier than they are released to the general public (and many of them are not released at all) as well as far more in-depth research than we make available to everybody. In addition, all subscribers can read any of my work without a subscription to Seeking Alpha Premium!We do note, however, that ...

CMS Energy Corporation (CMS) is making systematic investments to enhance its operations. It is also benefiting from delivering high-quality services to its consumers. The company is expanding its renewable power portfolio while eliminating coal-generating units.However, this Zacks Rank #3 (Hold) company is exposed to unfavorable costs associated with the shutdown of solid waste disposal facilities for coal ash.Factors Acting in Favor of CMS CMS Energy is investing heavily in infrastructure renovations and r ...

CMS Energy Corporation (CMS) recently revealed that its primary subsidiary, Consumer Energy, has been successful in eliminating 72,000 outages in 2024. The key to this success is the company’s significant investment in smart technology, specifically the use of Automatic Transfer Reclosers (ATRs). These devices have approximately saved more than 350,000 hours of potential power loss for CMS’ customers this year.This effort is part of Consumers Energy’s Reliability Roadmap to improve the grid. The company pla ...

The annual report, based on expert analysis and comprehensive data, recognized Wix as a leader in web accessibility and SEO   NEW YORK — Wix.com  (NASDAQ: WIX), the leading SaaS website builder platform globally1, earned top recognition in the 2024 Web Almanac report as the Most Accessible Website Platform CMS and Best SEO Performer. These distinctions reflect Wix's commitment to empowering users with tools that prioritize website accessibility and optimize discoverability.  This report, produced by the HTT ...

Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment ...

Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market YOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Limaca Medical Ltd. ("Limaca")'s Precision-GI™ motorized endoscopic biopsy device. Limaca's endoscopic device is designed to obtain improved biopsy results for patients with suspected gastrointestinal cancers such as pancr ...